Sanjay Chaube, MD
Internal Medicine · New Orleans, LANPI 1356458111
Payments from drug & device makers
Across 151 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$519
- AbbVie$431
- Amgen$424
- Mylan Specialty L.p.$396
- Johnson & Johnson$232
- Lilly USA, LLC$186
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,330100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $519 |
| AbbVie(2 entities) | 20 | $431 |
| Amgen | 24 | $424 |
| Mylan Specialty L.p. | 19 | $396 |
| Johnson & Johnson(2 entities) | 8 | $232 |
| Lilly USA, LLC | 7 | $186 |
| Sunovion Pharmaceuticals Inc. | 5 | $168 |
| Pfizer | 9 | $154 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $133 |
| Novartis | 5 | $89 |
| Astellas Pharma US Inc | 5 | $89 |
| Rigel Pharmaceuticals, Inc. | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Aurinia Pharma U.S., Inc. | 2 | $51 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Novo Nordisk | 2 | $37 |
| Nevro Corp. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Merz Pharmaceuticals, LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $20 |
| Merck | 1 | $17 |
| Nalpropion Pharmaceuticals LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$130
- VRAYLAR$125
- BREZTRI$125
- LONHALA MAGNAIR$102
- Repatha$101
How this compares
$3,336 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 25 | $41,548 |
| JardianceEmpagliflozin | 20 | $30,720 |
| EliquisApixaban | 22 | $28,863 |
| OzempicSemaglutide | 20 | $23,194 |
| JanuviaSitagliptin Phosphate | 11 | $13,919 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $2,844 |
| Pregabalin | 26 | $1,919 |
| Novolog FlexpenInsulin Aspart | 13 | $1,880 |
| Gabapentin | 81 | $1,324 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,299 |
| Atorvastatin Calcium | 125 | $1,154 |
| Metoprolol Succinate | 52 | $888 |
| Amlodipine Besylate | 129 | $756 |
| Losartan Potassium | 80 | $676 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 12 | $638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $186 | $41,54825 claims |
| PfizerEliquis | $154 | $28,86322 claims |
| Novo NordiskOzempic | $37 | $23,19420 claims |
| MerckJanuvia | $17 | $13,91911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- William SmithNew Orleans$50.5M
- Brian LewisNew Orleans$2M
- Steven DeitelzweigNew Orleans$939K
- Lydia BazzanoNew Orleans$892K
- Eboni Price-HaywoodNew Orleans$659K
- Susan Lewis AbdalianNew Orleans$301K
- Eduardo RodriguezNew Orleans$167K
- Shigeki SaitoNew Orleans$120K
- Jonathan GugelNew Orleans$95K
- Keith WinfreyNew Orleans$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.